Dasatinib-induced chylothorax in chronic myeloid leukemia
Zulfiqar Qutrio Baloch1, Shabber Agha Abbas1, Hammad Bhatti1
1Department of Internal Medicine, Brandon Regional Hospital, Brandon, Florida (Baloch, Braver); R-Research, Hamilton, New Jersey (Abbas); and Departments of Pulmonary Critical Care (Bhatti) and Internal Medicine/Palliative Care (Ali), Orlando Veterans Affairs Medical Center, Orlando, Florida.
Abstract:
Pulmonary adverse events are common abnormalities associated with the use of dasatinib in chronic myeloid leukemia. We present a case of a 69-year-old man who suddenly developed a rare chylothorax pulmonary adverse event following 10 months of dasatinib treatment.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
09:15Author Spotlight: Optimized Protocol for Detecting Antigen-Specific T Cells in Mouse Lungs Using Tetramers
Published on: July 19, 2024
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Targeted Cancer Therapies
There are several types of targeted therapies against...
